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Objective: The study aim was to assess the cumulative burden of polymorphisms located 
within four genetic loci previously associated with posttraumatic stress disorder (PTSD) among 
outpatients at risk for PTSD.
Methods: Diagnostic interviews were completed and DNA samples collected among 412 
pain patients to determine if FKBP5 (rs9470080), COMT (rs4680), CHRNA5 (rs16969968), 
and CRHR1 (rs110402) single nucleotide polymorphisms were cumulatively associated with 
increased risk for PTSD.
Results: In bivariate analyses, it was found that a count of specific PTSD risk alleles 
located within FKBP5, COMT, CHRNA5, and CRHR1 genetic loci (allele range = 0–6, mean 
count = 2.92, standard deviation = 1.36) was associated with lifetime (t [409] = 3.430, P = 0.001) 
and early onset PTSD (t [409] = 4.239, P = 0.000028). In logistic regression, controlling for 
demographic factors, personality traits, and trauma exposures, this risk allele count remained 
associated with both lifetime (odds ratio = 1.49, P = 0.00158) and early onset PTSD (odds 
ratio = 2.36, P = 0.000093). Interaction effects were also detected, whereby individuals with 
higher risk allele counts and higher trauma exposures had an increased risk of lifetime PTSD 
(allele count × high trauma, P = 0.026) and early onset PTSD (allele count × high trauma, 
P = 0.016) in these logistic regressions. Those with no or few risk alleles appeared resilient to 
PTSD, regardless of exposure history.
Conclusion: A cumulative risk allele count involving four single nucleotide polymorphisms 
located within the FKBP5, COMT, CHRNA5, and CRHR1 genes are associated with PTSD. 
Level of trauma exposure interacts with risk allele count, such that PTSD is increased in those 
with higher risk allele counts and higher trauma exposures. Since the single nucleotide poly-
morphisms studied encompass stress circuitry and addiction biology, these findings may have 
implications for neuropsychiatric research and treatment.
Keywords: posttraumatic stress disorder, genetic association study, single nucleotide 
  polymorphism, risk alleles, trauma exposure, neuroticism, childhood adversity
Introduction
While studies suggest that most adults have experienced lifetime traumatic events, 
relatively few of them develop posttraumatic stress disorder (PTSD).1–3 Available 
twin and family studies indicate that PTSD is at least moderately heritable, with 
approximately 30% of variance accounted for by genetic factors.4 To date several 
genetic components for PTSD have been identified that may explain this risk.5–7 These 
include biologic pathways involving the hypothalamic-pituitary-adrenal (HPA), locus 
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coeruleus-noradrenergic, and the limbic systems, among 
others.6,8–11 In the current study, genetic risk factors for PTSD 
were assessed among outpatients with chronic, nonmalignant 
pain, a condition often associated with PTSD.12
For the current study, four genetic markers were assessed 
using a cumulative risk allele model to test for an associa-
tion with PTSD among outpatients, similar to what has been 
undertaken to predict complex genetic associations in other 
clinical areas.13 To assess PTSD, a validated questionnaire 
based on the Diagnostic and Statistical Manual of Mental 
Disorder, Fourth Edition was used.2,14–17 Extending previous 
research,9 single nucleotide polymorphisms (SNPs) located 
within the FK506 binding protein-5 (FKBP5), catechol-O-
methyltransferase (COMT), cholinergic receptor nicotinic 
alpha-5 (CHRNA5), and the corticotropin-releasing   hormone 
receptor-1 (CRHR1) gene clusters were specifically geno-
typed and these markers were assessed for cumulative risk 
for PTSD.
The COMT gene is associated with anxiety disorders, 
psychosis, depression, and other conditions involving 
catecholamine pathway regulation and has recently been 
associated with PTSD.9,18,19 The FKBP5 gene regulates gluco-
corticoid receptor sensitivity, is functionally involved in HPA 
axis activity, and is associated with PTSD.5,6,9,20 The CHRNA 
gene cluster, which encodes components of the nicotinic ace-
tylcholine receptor, is associated with nicotine dependence 
and cigarette smoking,21,22 substance misuse,23 and recently 
PTSD.9 The CRHR1 gene is a polypeptide hormone and 
neurotransmitter involved in corticotropin-releasing hor-
mone activity associated with the stress response. Studies 
suggest that this gene also regulates HPA axis function and 
is associated with the impact of traumatic stress exposure 
and PTSD.20,24
Methods
Subjects
Study subjects were adult outpatients ($18 years old) who 
were prescribed pain medications for nonmalignant pain 
for $4 months.14,23 Chronic pain patients typically have 
a high prevalence of PTSD.25,26 The mean age of patients 
was 55 years old (standard deviation = 13.4) and the preva-
lence of lifetime PTSD was 15% (95% confidence interval 
[CI] = 11.7–18.1). The sample was randomly selected from 
among a population of chronic pain outpatients identified by 
query of the electronic health records of the Geisinger Clinic, 
an integrated health system that serves residents of 40 central 
and northeastern Pennsylvania counties.14 Geisinger’s ambu-
latory clinics have used the Epic (Epic Systems Corporation, 
Verona, WI) outpatient electronic health record system 
since 2001. With patient consent, trained and supervised 
  interviewers administered structured diagnostic telephone 
interviews from August 2007 through November 2008.
Phenotypic and confounding measures
Study interviewers administered diagnostic surveys using 
instruments used in past research.2,16,17 To meet criteria 
for lifetime PTSD, patients had to meet the full diagnostic 
criteria for PTSD, known as the “A through F” criteria.2,15 
These criteria include experiencing intense fear (criterion A), 
  re-experiencing the event (criterion B), avoidance of stimuli 
associated with the event (criterion C), experiencing increased 
arousal (criterion D), experiencing symptoms for a month or 
more (criterion E), and experiencing psychological distress 
or impairment (criterion F). To be diagnosed with early onset 
PTSD, the patient had to meet the A–F diagnostic criteria 
for PTSD before the age of 35 years. Research typically 
suggests that early onset PTSD likely has greater impact on 
trauma victims.27,28 Over half (53%) of the PTSD cases in 
the current study met this early onset definition. Research 
instruments relevant to childhood adversity, lifetime trauma 
exposure, and self-esteem were also administered.17,29–31 To 
assess neuroticism, also a risk factor for PTSD,32 the NEO 
Five-Factor Inventory was used.33
The childhood adversity scale used was the Adverse 
Childhood Experiences scale, a widely used measure of 
childhood adversity with good reported reliability and 
validity.29,30,34 Cronbach’s alpha for the Adverse Childhood 
Experiences scale in the current study was 88. The trauma 
scale used was a measure that has been extensively used in 
past trauma research and has been shown to have excellent 
predictive validity.16,17,35 In the current study, this measure 
consisted of a count of the number of traumatic events (eg, 
combat exposure, sexual assault, major disaster) that the per-
son experienced in his/her lifetime (range 0–9, mean = 2.19, 
standard deviation = 2.0). Self-esteem was measured by the 
Rosenberg Self-Esteem Scale, a widely used construct to 
measure self-esteem.31,36 In the current study, Cronbach’s 
alpha was 80 for this scale. The NEO Five-Factor Inventory 
is a personality measure widely used in neuropsychiatric 
research.33,37,38 This scale is reported to have good reliability 
and validity.37,38 Cronbach’s alpha for the scales used in the 
NEO are good, typically between 0.76–0.89.39
Given that the current study population was drawn from a 
sample of pain patients, the study results were also adjusted 
for prescription opioid dependence, level of pain impair-
ment, and the number of opioid prescriptions received as 
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potential confounders. Opioid dependence was based on 
whether the subject met criteria for Diagnostic and Statistical 
Manual of Mental Disorder, Fourth Edition drug dependence 
and was based on a diagnostic interview.14 Pain assessment 
was based on the Brief Pain Inventory, a widely used and 
validated instrument.40,41 The number of opioid prescriptions 
received over the past 3 years was based on electronic health 
record data. Finally, to potentially account for population 
stratification, the study results were also adjusted for ances-
try status, based on country of origin, coded as Northern 
European, Eastern European, Southern European, and other. 
Non-Caucasians were excluded from these analyses. This 
study was approved by the Geisinger Clinic’s Institutional 
Review Board.
DNA collection and genotyping
Following the study interview, buccal swab kits were mailed 
to consenting adults. Altogether, 412 returned the buccal swab 
kit with adequate DNA for the current analyses. Two subjects 
were identified as non-Caucasian and were not included in 
the current study analyses, as noted. The candidate genes 
studied (and corresponding SNPs) were: COMT (rs4680), 
FKBP5 (rs9470080), CHRNA5 (rs16969968), and CRHR1 
(rs110402). The SNPs for the four target loci were originally 
selected using linkage disequilibrium tagging with consider-
ation of prior evidence and functional annotation.42 For each 
gene, the location of the main association signals related to 
PTSD were determined from the relevant   literature. The 
linkage disequilibrium structure of the gene in the   HapMap 
Caucasian sample (release 23a; http://www.hapmap.org) was 
then examined using the Gabriel algorithm.43 The algorithm 
of de Bakker implemented in the software HaploView 4.0 
(Daly Lab, Broad Institute, Cambridge, MA) was then used 
to select tagged SNPs for the target block in each gene.44 
The Gabriel algorithm delineates boundaries of genomic 
  markers identified as haplotype blocks with little evidence 
for historical recombination, within which only a few 
  common   haplotypes are observed and that can be tagged for 
  association analysis using unsaturated SNP subsets.43 The de 
Bakker approach selects tags from empirical data based on 
linkage disequilibrium to maximize the cost-effectiveness of 
using a limited number of typed SNPs in a locus.44
Genotyping was performed on an Applied BioSystems® 
7500 Real-Time Polymerase Chain Reaction System using 
TaqMan® kits (Applied BioSystems, Foster City, CA), 
  following the manufacturer’s protocols. Quality control mea-
sures included visual inspection of the allelic discrimination 
plots, monitoring concordance of cross-plated duplicate pairs, 
monitoring the overall call rate, and monitoring agreement 
with Hardy–Weinberg expectations.45
Statistical analyses
Based on previous research,9 a bivariate association with 
PTSD was tested for the four target SNPs in the current study 
and each of these was found to be significant (P , 0.05). 
A cumulative risk allele model that included these four SNPs 
was then developed, as has been done in other clinical areas.13,46 
As suggested, each of these target SNPs had been associated 
with PTSD in previous reports. For each SNP studied, as 
previously discussed, an additive coding scheme (ie, subjects 
assigned zero, one, or two according to the number of copies 
of the minor allele) was tested followed by a dominant/reces-
sive coding scheme (ie, carriers and homozygotes for the 
tested allele assigned a value of one, versus homozygotes for 
the alternate allele assigned a value of zero) if the additive 
model was not significant. Only one SNP tested was reduced 
to a dominant/recessive model (Table 1).9 A count of alleles 
across these loci resulted in a risk score ranging from 0–6 
(mean = 2.92, standard deviation = 1.36). For descriptive 
analyses, chi-squared tests were used to assess the associa-
tions between the main variables of interest and PTSD status 
(Table 2). In addition, independent t-tests were also used to 
assess the bivariate association between risk allele counts 
and key exposure variables, which included trauma exposure, 
Table 1 Single nucleotide polymorphisms included in risk allele model
SNP Gene Chromosome  
(map location)
MAF  
(minor/common)
Functional  
annotation
HWE 
P value
Marker specifications (NCBI build 37.1)
rs16969968* CHRNA5 15 (78882925) 35.0% (A/G) Missense (D⇔N) 0.0279
rs9470080** FKBP5 6 (35646435) 33.0% (T/C) intron 0.7404
rs4680* COMT 22 (19951271) 49.5% (G/A) Missense (V⇔M) 0.9709
rs110402* CRHR1 17 (43880047) 42.4% (A/G) intron 0.4333
Notes: *Additive model coded 0, 1, 2 for risk allele; **dominant model coded 0, 1 for the risk allele.
Abbreviations: HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; NCBi, National Center for Biotechnology information (Bethesda, MD); SNP, single 
nucleotide polymorphism.
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Table 2 Lifetime posttraumatic stress disorder and early onset posttraumatic stress disorder by study variables
Study  
variables
% total (N) Lifetime PTSD Early onset PTSD
% yes (N) % no (N) P value % yes (N) % no (N) P value
Sex
  Male 
  Female
30.2 (152) 
68.9 (351)
9.9 (15) 
16.8 (59)
90.1 (137) 
83.2 (292)
0.044 4.6 (7) 
9.1 (32)
95.4 (145) 
90.9 (319)
0.082
Age (years)
  18–44 
  45–64 
  65+
17.3 (87) 
58.3 (293) 
24.5 (123)
25.3 (22) 
15.4 (45) 
5.7 (7)
74.7 (65) 
84.6 (248) 
94.3 (116)
,0.0001 24.1 (21) 
5.5 (16) 
1.6 (2)
75.9 (66) 
94.5 (277) 
98.4 (121)
,0.0001
Married
  No 
  Yes
38.2 (192) 
61.8 (311)
19.8 (38) 
11.6 (36)
80.2 (154) 
88.4 (275)
0.011 10.9 (21) 
5.8 (18)
89.1 (171) 
94.2 (293)
0.036
High school education or less
  No 
  Yes
50.1 (252) 
49.9 (251)
15.5 (39) 
13.9 (35)
84.5 (213) 
86.1 (216)
0.628 9.5 (24) 
6.0 (15)
90.5 (228) 
94.0 (236)
0.137
income less than $30,000
  No 
  Yes
57.5 (289) 
42.5 (214)
11.4 (33) 
19.2 (41)
88.6 (256) 
80.8 (173)
0.015 5.5 (16) 
10.7 (23)
94.5 (273) 
89.3 (191)
0.031
High trauma exposure
  No 
  Yes
78.5 (395) 
21.5 (108)
10.9 (43) 
28.7 (31)
89.1 (352) 
71.3 (77)
,0.0001 4.3 (17) 
20.4 (22)
95.7 (378) 
79.6 (86)
,0.0001
High childhood adversity
  No 
  Yes
73.2 (368) 
26.8 (135)
10.1 (37) 
27.4 (37)
89.9 (331) 
72.6 (98)
,0.0001 3.8 (14) 
18.5 (25)
96.2 (354) 
81.5 (110)
,0.0001
High neuroticism
  No 
  Yes
78.3 (394) 
21.7 (109)
10.4 (41) 
30.3 (33)
89.6 (353) 
69.7 (76)
,0.0001 6.1 (24) 
13.8 (15)
93.9 (370) 
86.2 (94)
0.008
High self-esteem
  No 
  Yes
80.1 (403) 
19.9 (100)
17.4 (70) 
4.0 (4)
82.6 (333) 
96.0 (96)
0.001 8.9 (36) 
3.0 (3)
91.1 (367) 
97.0 (97)
0.047
Abbreviation: PTSD, posttraumatic stress disorder.
adversity exposure, neuroticism level, self-esteem, as well as 
PTSD status (Table 3). Next, multivariate logistic regressions 
were used to test for an association of genetic risk allele 
count with PTSD status, controlling for potential confound-
ing (Table 4).42,47 Gene × environmental exposure interaction 
effects were specifically tested for (Table 5), since these have 
been previously reported for some of these loci.5,20 For these 
interaction assessments, lifetime trauma and childhood adver-
sity were classified as high versus not, based on the upper 
quintile or quartile range for lifetime trauma and childhood 
adversity, respectively. Specific gene × environment interaction 
effects were statistically evaluated by use of a cross-product 
term for risk allele-count × trauma exposure (or childhood 
adversity) in multivariate logistic regressions that included the 
main effects (ie, risk allele count and the respective environ-
mental exposure) and predicted PTSD status. As suggested, 
given the current study population, prescription opioid depen-
dence, pain impairment, and the number of opioid prescrip-
tions received were also assessed as potential confounders as 
a final regression step. For data analyses, Stata® version 11.2 
(StataCorp LP, College Station, TX) was used.
Results
The bivariate analysis confirmed that all four target SNPs 
were associated with lifetime PTSD (P , 0.05), including 
FKBP5 (rs9470080), COMT (rs4680), CHRNA5 (rs16969968), 
and CHRR1 (rs110402) SNPs. For each of these target 
SNPs, Table 1 shows the chromosomal location, minor allele 
frequency, functional annotation, and Hardy–Weinberg equi-
librium results. All four SNPs studied met expectations for 
Hardy–Weinberg equilibrium (P . 0.025). Table 2 shows 
the association between lifetime and early onset PTSD and 
the main study variables. As can be seen, lifetime PTSD is asso-
ciated with female sex, younger age, being unmarried, having 
lower household income, having higher trauma exposure, 
having higher childhood adversity, having higher neuroticism, 
and having lower self-esteem (all P values ,0.05).
Table 3 shows the unadjusted risk allele count results 
by PTSD status and key study variables. The prevalence of 
lifetime PTSD in the study was 14.7% (95% CI = 11.7–18.1) 
and the prevalence of early onset PTSD was 7.6% (95% 
CI = 5.1–10.7) (Table 3). As can be seen, both lifetime 
(P = 0.001) and early onset (P = 0.000028) PTSD were 
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Table 3 Mean risk allele counts by posttraumatic stress disorder 
status and key study variables (mean risk allele count = 2.92, 
standard deviation = 1.36)
Study 
variables
Risk allele 
counts 
Mean (n)
t-test Difference P value
Lifetime PTSD*
  No 
  Yes
2.83 (352) 
3.47 (59)
– 
3.430
– 
0.648
– 
0.001
Early onset PTSD**
  No 
  Yes
2.84 (382) 
3.93 (29)
– 
4.239
– 
1.09
– 
0.000028
High trauma
  No 
  Yes
2.90 (324) 
2.98 (87)
– 
0.442
– 
0.073
– 
0.659
High adversity
  No 
  Yes
2.87 (293) 
3.05 (118)
– 
1.241
– 
0.184
– 
0.215
High neuroticism
  No 
  Yes
2.92 (323) 
2.91 (88)
– 
0.083
– 
0.014
– 
0.934
High self-esteem
  No 
  Yes
2.90 (325) 
3.01 (86)
– 
0.704
– 
0.116
– 
0.482
Notes:  *Prevalence  of  lifetime  posttraumatic  stress  disorder  =  14.7%  (95% 
confidence interval = 11.7–18.1); **prevalence of early onset posttraumatic stress 
disorder = 7.6% (95% confidence interval = 5.1–10.7).
Abbreviation: PTSD, posttraumatic stress disorder.
Table 4 Multivariate logistic regressions predicting lifetime and early onset posttraumatic stress disorder from risk allele count, 
controlling for key risk factors and potential confounders
Study variables Lifetime PTSD† Early onset PTSD†
OR (95% CI) P value OR (95% CI) P value
Risk allele count (0–6)* 1.49 (1.16–1.90) 0.00158 2.36 (1.53–3.62) 0.000093
High trauma 
  No (ref) 
  Yes
 
1.00 
2.03 (1.00–4.11)
 
– 
0.049
 
1.00 
5.21 (1.93–14.09)
 
– 
0.0011
High adversity 
  No (ref) 
  Yes
 
1.00 
1.52 (0.79–2.92)
 
– 
0.209
 
1.00 
3.90 (1.44–10.55)
 
– 
0.0074
High neuroticism 
  No (ref) 
  Yes
 
1.00 
3.31 (1.72–6.37)
 
– 
0.0003
 
1.00 
1.74 (0.64–4.74)
 
– 
0.282
High self-esteem 
  No (ref) 
  Yes
 
1.00 
0.23 (0.05–1.03)
 
– 
0.055
 
1.00 
0.94 (0.18–4.84)
 
– 
0.939
Notes: *Risk allele count coded as a continuous variable, coded 0–6; †logistic regression model includes risk allele count, trauma exposure, childhood adversity, neuroticism, 
and self-esteem, plus age (in years), sex, income, and marital status as covariates.
Abbreviations: CI, confidence interval; OR, odds ratio; PTSD, posttraumatic stress disorder.
associated with higher risk allele counts. Trauma exposure, 
childhood adversity, neuroticism, and self-esteem were not 
associated with risk allele counts (all P values .0.05).
Table 4 presents the multivariate logistic regression results 
for lifetime and early onset PTSD. As can be seen, after 
controlling for demographic factors, trauma exposures and 
psychological traits (ie, neuroticism and self-esteem), risk 
allele count was significant for lifetime PTSD (odds ratio 
[OR] = 1.49, P = 0.00158). Noteworthy is that high trauma 
exposure (P = 0.049) and high neuroticism (P = 0.0003) were 
significant in this adjusted lifetime PTSD model. For early 
onset PTSD, the multivariate logistic regression results were 
highly significant (OR = 2.36, P = 0.000093). In contrast to 
lifetime PTSD, significant variables in this early onset model 
included high trauma exposure (P = 0.0011) and high child-
hood adversity (P = 0.0074). These logistic regression data 
suggest that those with six or more risk alleles have about 
nine times greater risk of lifetime PTSD (6 × 1.49 ≈ 9) and 
that those with six or more risk alleles have about 14 times 
greater risk of early onset PTSD (6 × 2.36 ≈ 14) than those 
with no risk alleles, respectively (Table 4).
Following assessment of main effect models, interaction 
effects were evaluated for allele count × high trauma and 
allele count × high adversity exposure for both lifetime and 
early onset PTSD (Table 5). These interaction effects were 
significant for risk allele count × high trauma exposure for 
both lifetime (OR = 2.05, P = 0.026) and early onset PTSD 
(OR = 3.47, P = 0.016) (Table 5). These interactions suggest 
that individuals with higher risk allele counts and higher 
trauma exposures had an increased risk of PTSD. However, 
the interaction effect for risk allele count × high childhood 
adversity was not significant in either the lifetime or early 
onset PTSD model (available upon request).
Figure 1 shows the prevalence of both lifetime and early 
onset PTSD by risk allele burden. As seen, those with less 
than two risk alleles have a low prevalence of PTSD. By 
comparison, those with four or more risk alleles have a 
prevalence of lifetime PTSD of more than 20%. These data 
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Table 5 Multivariate logistic regression interactions for lifetime and early onset posttraumatic stress disorder showing risk allele 
count × high trauma exposure effect
Study variables Lifetime PTSD† Early onset PTSD†
OR (95% CI) P value OR (95% CI) P value
Risk allele count* 1.24 (0.94–1.65) 0.131 1.51 (0.92–2.50) 0.104
High trauma** 0.19 (0.02–1.79) 0.146 0.06 (0.01–2.40) 0.132
Risk allele count × high trauma 2.05 (1.09–3.87) 0.026 3.47 (1.27–9.53) 0.016
Notes: *Risk allele count coded as a continuous variable, coded 0–6; **high trauma coded as binary variable, coded 0, 1; †logistic regression model includes risk allele count, 
trauma exposure, childhood adversity, neuroticism, and self-esteem, plus age (in years), sex, income, and marital status as covariates. The interaction effect (ie, risk allele 
count × trauma exposure) has been added to this model.
Abbreviations: CI, confidence interval; OR, odds ratio; PTSD, posttraumatic stress disorder.
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Figure 1 Prevalence of lifetime posttraumatic stress disorder and early onset posttraumatic stress disorder by risk allele burden.
Abbreviation: PTSD, posttraumatic stress disorder.
suggest that those with no or few risk alleles may be resilient 
to PTSD, regardless of environmental exposures, since these 
exposures were not associated with allele burden (Table 3) 
or with significant confounding of the association between 
allele count and PTSD (Table 4). This suggests that the 
main exposures known to cause PTSD – psychological 
trauma – did not vary by risk allele count. However, those 
with higher risk allele counts and high trauma exposure 
have an increased risk of PTSD (Table 5), indicating that a 
gene × environmental effect is present for risk allele count 
by level of trauma exposure.
As suggested, since the study population included 
  Caucasian pain patients on pain medications, pain status, drug 
dependence status, the number of prescription orders for pain 
medicines were also controlled for, but these variables had 
little impact on the final regression results. Based on previous 
research, since a dominant model for SNP marker rs9470080 
(FKBP5) – and not the other three markers – was used, a risk 
allele model that included all four SNPs was also assessed as 
additive risk allele markers (ie, all four SNPs coded zero, one, 
or two). This additive model produced similar results in the 
logistic regressions. Finally, ancestry status was also entered 
into the final logistic regression models and this adjustment 
also made little difference.
Discussion
Examination of risk allele counts by PTSD status, as coded 
in the regression models, suggested that the “A” allele of 
rs16969968 (CHRNA5) and rs4680 (COMT), the “T” allele of 
rs9470080 (FKBP5), and the “G” allele of rs110402 (CRNR1) 
are more common among PTSD cases than non-PTSD cases. 
Thus, this study confirmed that SNP markers rs16969968(A), 
rs9470080(T), rs4680(A), and rs110402(G) were each indi-
vidually associated with PTSD. When these SNP markers 
were combined into a cumulative risk allele model (Table 3), 
the bivariate t-test results were significant for both lifetime 
(P = 0.001) and early onset PTSD (P = 0.000028). In multi-
variate analyses controlling for potential confounders, both 
lifetime (OR = 1.49, P = 0.00158) and early onset PTSD 
(OR = 2.36, P = 0.000093) remained significant. Interactions 
were also detected for risk allele count × trauma exposure for 
both lifetime (P = 0.026) and early onset PTSD (P = 0.016). 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
136
Boscarino et alNeuropsychiatric Disease and Treatment 2012:8
The final cumulative risk model suggests that the risk for 
lifetime PTSD was about nine times higher among those 
with six or more risk alleles (1.49 × 6 ≈ 9), compared to those 
with no risk alleles. For early onset PTSD, this risk was about 
14 times higher among those with six or more risk alleles 
(2.36 × 6 ≈ 14).
FKBP5 polymorphisms are known to regulate the cortisol-
binding affinity and nuclear translocation of the glucocorticoid 
receptor and polymorphisms at the FKBP5 locus have been 
reported to interact with exposure to child adversity in predict-
ing PTSD.5,48 COMT polymorphisms have been found to affect 
fear extinction and are thought to play a role in the etiology of 
anxiety disorders.9,19,49 The CHRNA5 gene has been associated 
with smoking and nicotine dependence.21,22 PTSD is known to 
be associated with cigarette smoking.50 This locus has recently 
been associated with PTSD and is likely involved in mamma-
lian fear circuitry.9 Research suggests that the CRHR1 gene 
regulates HPA axis function in conjunction with exposure to 
early life trauma.20 In addition, corticotropin-releasing hormone 
is thought to play a role in the pathophysiology of stress-related 
psychiatric disorders, such as major depressive disorder and 
PTSD.24 It has been suggested that corticotropin-releasing 
hormone contributes to alterations in memory formation in 
PTSD cases and that this hormone influences hippocampal 
regulation of the HPA axis.24 Note that the assignment of risk 
alleles for the SNP variants examined in the current study agree 
with prior findings for the FKBP5, CRHR1, and COMT genetic 
variants.5,51–53 A 2011 paper, based on this same cohort,9 was the 
first to associate a CHRNA5 genetic variant with PTSD, so the 
risk allele assignment in the current paper would be consistent 
with that earlier paper.
It is noteworthy that research suggests that PTSD is 
associated with an increased prevalence of chronic health 
conditions, including cardiovascular disease, rheumatoid 
arthritis, and other chronic diseases.54–60 Studies suggest that 
PTSD may result in inflammatory injuries through overacti-
vation of the HPA and sympathetic-adrenal-medullary stress 
axes, subsequently followed by hypocortisolism related to 
molecular downregulation of these systems.54,61,62 Epigenetic-
related phenomena are also suspected.63,64 Consistent with 
these findings, current research suggests that low-grade 
systemic inflammatory activity is common in PTSD.65–68 This 
PTSD-disease link also could be related to adverse health 
behaviors, such as cigarette smoking and substance misuse 
related to self-regulation of aversive psychological states 
brought on by PTSD.69,70
Study limitations for this research include the fact that 
the interview data were based on self-report, the total sample 
size was limited, and the study participants were more often 
female and drawn from a pain population. Also, multiple 
comparisons were not adjusted for and population stratifi-
cation using genetic methods were not taken into account, 
although final regression results were adjusted for reported 
ancestry and all non-Caucasians were eliminated from the 
analyses to control for stratification. These factors may have 
biased the results and could limit study generalization. Also, 
the total number of PTSD cases in the study was limited 
(n = 59). Thus, the findings will require further replication.
The current research suggests that FKBP5, COMT, 
CHRNA5, and CRHR1 genetic loci involving biologic 
pathways encompassing inflammatory mechanisms, nico-
tine dependence, substance misuse, sleep regulation, and 
fear circuitry, among others, are associated with PTSD and 
interact with levels of trauma exposure.9 These genetic loci 
seem worthy of research related to the behavioral genetics 
of PTSD as well as related to chronic disease onset. For 
example, researchers have reported that CHRNA gene is 
associated with lung cancer.71 This gene was also recently 
associated with cigarette smoking and nicotine dependence.23 
Thus, the causal pathway for lung cancer involving these 
loci appears to involve nicotine addiction associated with 
alterations in nervous system molecular biology. Without 
this compulsive addiction behavior, there would likely be 
insufficient exposure to cigarette smoke to result in lung 
cancer for most individuals.
Similarly, the genetic components involved in PTSD, 
including the FKBP5, COMT, CHRNA5, and CRHR1 genes, 
may be associated with the pathophysiology of specific 
diseases following PTSD onset. Recently it was reported 
that CHRNA was not only associated with lung cancer but 
also with peripheral arterial disease.22 PTSD has also been 
associated with metabolic syndrome.72 Since the risk alleles 
studied appear to encompass multiple, interrelated disease 
pathways, these genetic markers may have research impli-
cations for neuropsychiatric research and treatment. The 
absence of PTSD among those with no or few risk alleles 
is intriguing and also worthy of investigation. The authors 
suspect that genetic resilience, in this case the absence of 
PTSD risk alleles, may also be associated with chronic dis-
ease resilience, but further research is required to confirm 
this hypothesis.
Previous presentation
Preliminary results from this study were presented at: The 
31st Annual Anxiety Disorders Association of America 
Conference, New Orleans, LA, March 25, 2011.
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